Robbins Arroyo LLP Is Investigating the Officers and Directors of Halozyme Therapeutics, Inc. on Behalf of Shareholders

SAN DIEGO, April 17, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) breached their fiduciary duties to shareholders.  Halozyme is a biopharmaceutical company that researches, develops, and commercializes human enzymes that facilitate the delivery of injected drugs and fluids.

View the investigation on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/halozyme-therapeutics-inc/

Halozyme Shares Drop on Halt of PEGPH20 Phase 2 Trial

On April 4, 2014, Halozyme issued a press release announcing that patient enrollment and dosing of PEGPH20 would be halted in the Phase 2 trial of evaluating PEGPH20 in patients with pancreatic cancer.  The suspension of the trial followed the recommendation of the independent Data Monitoring Committee, while it assess "clinical data that indicates a possible difference in the thromboembolic event rate between the group of patients treated with PEGPH20, nab-paclitaxel and gemcitabine versus the group of patients treated with nab-paclitaxel and gemcitabine without PEGPH20." On this news, shares of Halozyme fell $3.16, or 27%, to close at $8.43 on April 4, 2014.  Then on April 9, 2014, Halozyme announced that the U.S. Food and Drug Administration had placed a clinical hold on patient enrollment and dosing of PEGPH20.

Halozyme Residential Shareholders Have Legal Options

Robbins Arroyo LLP highlights that Halozyme shareholders have the option to pursue a shareholder litigation demand or shareholder derivative action through which shareholders aim to hold insider wrongdoers accountable for their actions, prevent future misconduct, and bring long-term value back to the company.  Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at [phone], [e-mail], or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. 

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
[e-mail]
[phone] or Toll Free [phone]
www.robbinsarroyo.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36754LOGO

SOURCE Robbins Arroyo LLP

Copyright 2014 PR Newswire